Phase I Clinical Trial of Alitretinoin and Tamoxifen in Breast Cancer Patients: Toxicity, Pharmacokinetic, and Biomarker Evaluations - Concepedia

Concepedia

Publication | Closed Access

Phase I Clinical Trial of Alitretinoin and Tamoxifen in Breast Cancer Patients: Toxicity, Pharmacokinetic, and Biomarker Evaluations

50

Citations

57

References

2001

Year

Julia Lawrence, Peter C. Adamson, Rafael C. Caruso, Catherine Chow, David E. Kleiner, Robert F. Murphy, David Venzon, Margaret Shovlin, Marianne Noone, Maria J. Merino,

Journal of Clinical Oncology

Abstract

The combination of tamoxifen and alitretinoin is well tolerated and has antitumor activity in metastatic breast cancer. The recommended phase II dose is 70 mg/m2/d with 20 mg/d tamoxifen.

References

	Year	Citations

Page 1